TY - JOUR
T1 - Current bladder cancer tests
T2 - Unnecessary or beneficial?
AU - Simon, Michael A.
AU - Lokeshwar, Vinata B.
AU - Soloway, Mark S.
N1 - Funding Information:
Dr. Vinata Lokeshwar completed her Bachelor and Master of Science degrees in microbiology in India and her doctoral degree in Cellular and Molecular Biology from St. Louis University. Dr. Lokeshwar joined the department of Cell Biology and Anatomy at the University of Miami School of Medicine as a postdoctoral fellow. During her fellowship, Dr. Lokeshwar was awarded an American Heart and National Institutes of Health (NIH) fellowship. Dr. Lokeshwar currently holds a joint faculty position in the Department of Cell Biology and Anatomy.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These same tests are used to monitor patients with a history of bladder cancer for recurrence. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist and is costly. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently many non-invasive bladder cancer tests, utilizing markers found in the urine, have been developed. The FDA has approved several of these for the use is bladder cancer diagnosis, and many others are undergoing development and investigation. An ideal bladder cancer test would be non-invasive, highly sensitive and specific, inexpensive, easy to perform, and yield highly reproducible results. Many of the tests reviewed meet some, but not all, of these criteria.
AB - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These same tests are used to monitor patients with a history of bladder cancer for recurrence. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist and is costly. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently many non-invasive bladder cancer tests, utilizing markers found in the urine, have been developed. The FDA has approved several of these for the use is bladder cancer diagnosis, and many others are undergoing development and investigation. An ideal bladder cancer test would be non-invasive, highly sensitive and specific, inexpensive, easy to perform, and yield highly reproducible results. Many of the tests reviewed meet some, but not all, of these criteria.
KW - Bladder
KW - Bladder cancer
KW - Tumor markers
UR - http://www.scopus.com/inward/record.url?scp=0041666602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041666602&partnerID=8YFLogxK
U2 - 10.1016/S1040-8428(03)00074-X
DO - 10.1016/S1040-8428(03)00074-X
M3 - Review article
C2 - 12900004
AN - SCOPUS:0041666602
SN - 1040-8428
VL - 47
SP - 91
EP - 107
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
IS - 2
ER -
